Overactive Bladder

Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® for Patients with Overactive Bladder April 12, 2021

Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients. April 11, 2021

Clinical efficacy of transcutaneous tibial nerve stimulation (TTNS) versus sham therapy (part I) and TTNS versus percutaneous tibial nerve stimulation (PTNS) (part II) on the short term in children with the idiopathic overactive bladder syndrome: protocol April 11, 2021

Bladder wall micromotion measured by non-invasive ultrasound: initial results in women with and without overactive bladder. April 11, 2021

Triple Therapy with Tamsulosin, Dutasteride, and Imidafenacin for Benign Prostatic Hyperplasia in Patients with Overactive Bladder Symptoms Refractory to Tamsulosin: Subgroup Analyses of the DIrecT Study. April 4, 2021

Prevalence and Factors Associated with Cumulative Anticholinergic Burden Among Older Long-Stay Nursing Home Residents with Overactive Bladder. April 4, 2021

Can We Rely Solely on the International Prostate Symptoms Score to Investigate Storage Symptoms in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement? Findings from a Cross-sectional Study. March 28, 2021

Randomized clinical trials assessing third-line therapies to treat non-neurogenic overactive bladder syndrome: a review about methodology. March 28, 2021

Outcomes of a single trigone-only vs. 20 trigone-sparing injections of OnabotulinumtoxinA for refractory overactive bladder (OAB). March 21, 2021

A prospective observational study of urinary cytokines and inflammatory response in patients with Overactive Bladder Syndrome. March 21, 2021

Clustering of patients with overactive bladder syndrome. March 21, 2021

Social media analytics of overactive bladder posts: what do patients know and want to know? March 14, 2021

Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions. March 14, 2021

The relationship between overactive bladder and prostate cancer: A scoping review. March 14, 2021

Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis. March 7, 2021

Possible involvement of muscarinic receptor blockade in mirabegron therapy for patients with overactive bladder. March 7, 2021

Percutaneous tibial nerve stimulation for idiopathic and neurogenic overactive bladder dysfunction: a four-year follow-up single-centre experience. February 28, 2021

Treatment outcomes of overactive bladder with combined therapies of botulinum toxin injections and oral agents. February 28, 2021

Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder. February 21, 2021

Cognitive components of behavioral therapy for overactive bladder: a systematic review. February 21, 2021

Page 1 of 94